<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00117442</url>
  </required_header>
  <id_info>
    <org_study_id>20010191</org_study_id>
    <nct_id>NCT00117442</nct_id>
  </id_info>
  <brief_title>A Study of Carboplatin/Paclitaxel With Pegfilgrastim Supported by Haematopoietic Progenitor Cell Re-Infusion in Whole Blood</brief_title>
  <official_title>An Open-Label, Randomised Study of Multi-Cycle, Dose Intensive Carboplatin/Paclitaxel With Pegfilgrastim Supported by Haematopoietic Progenitor Cell Re-Infusion in Whole Blood</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Amgen</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to provide dose-finding information regarding the efficacy and
      kinetics of peripheral blood progenitor cell (PBPC) mobilisation by pegfilgrastim and to
      determine if carboplatin/paclitaxel can be delivered at a reduced cycle interval when
      supported by pegfilgrastim-mobilised PBPCs in whole blood.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2002</start_date>
  <completion_date type="Actual">December 2004</completion_date>
  <primary_completion_date type="Actual">August 2004</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PBPC mobilization profiles and success rate of achieving planned chemotherapy administration on time.</measure>
    <time_frame>Cycle 0, and through 4 cycles</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>PBPC kinetics and response to chemotherapy treatment</measure>
    <time_frame>Cycles 1-4</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">61</enrollment>
  <condition>Breast Cancer</condition>
  <condition>Lung Cancer</condition>
  <condition>Ovarian Cancer</condition>
  <arm_group>
    <arm_group_label>Pegfilgrastim 18 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pegfilgrastim 18 mg given once for mobilization</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Filgrastim</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Filgrastim given daily for mobilization</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pegfilgrastim 12 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pegfilgrastim 12 mg given once for mobilization</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pegfilgrastim 6 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pegfilgrastim 6 mg given once for mobilization</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>carboplatin</intervention_name>
    <description>Chemotherapy</description>
    <arm_group_label>Pegfilgrastim 6 mg</arm_group_label>
    <arm_group_label>Pegfilgrastim 18 mg</arm_group_label>
    <arm_group_label>Filgrastim</arm_group_label>
    <arm_group_label>Pegfilgrastim 12 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>paclitaxel</intervention_name>
    <description>chemotherapy</description>
    <arm_group_label>Pegfilgrastim 6 mg</arm_group_label>
    <arm_group_label>Pegfilgrastim 18 mg</arm_group_label>
    <arm_group_label>Filgrastim</arm_group_label>
    <arm_group_label>Pegfilgrastim 12 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pegfilgrastim</intervention_name>
    <description>Growth factor for mobilization</description>
    <arm_group_label>Pegfilgrastim 6 mg</arm_group_label>
    <arm_group_label>Pegfilgrastim 18 mg</arm_group_label>
    <arm_group_label>Pegfilgrastim 12 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria: - Pathologically confirmed diagnosis of malignancy (solid tumour)
        suitable for treatment with intensified carboplatin and paclitaxel - Previously untreated
        with chemotherapy or radiotherapy - ECOG performance status 0 to 2 inclusive - Life
        expectancy greater than or equal to 12 weeks - ANC greater than or equal to 2.0 x 10^9/L,
        platelets greater than 100 x 10^9/L - Glomerular filtration rate greater than 60 mL/min
        Exclusion Criteria: - Active infection requiring treatment with systemic (IV or oral)
        anti-infectives (antibiotic, antifungal, antiviral) within 72 hours of randomisation -
        Known to be HIV positive - Any premalignant myeloid condition or any malignancy with
        myeloid characteristics (e.g., myelodysplastic syndromes, acute or chronic myelogenous
        leukaemia) - Prior malignancy within the last 5 years, with the exception of surgically
        cured basal/squamous skin cell carcinoma, and/or carcinoma of the cervix in-situ - History
        of impaired cardiac status [e.g., severe heart disease (NYHA greater than 2),
        cardiomyopathy, or congestive heart failure] - Bone marrow involvement of disease - Major
        surgery within 2 weeks before randomisation - Known sensitivity to E. coli derived drug
        products (e.g., filgrastim) - Previous exposure to pegfilgrastim
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MD</last_name>
    <role>Study Director</role>
    <affiliation>Amgen</affiliation>
  </overall_official>
  <removed_countries>
    <country>United Kingdom</country>
  </removed_countries>
  <link>
    <url>http://www.neulasta.com/</url>
    <description>FDA-approved Drug Labeling</description>
  </link>
  <link>
    <url>http://www.amgentrials.com</url>
    <description>AmgenTrials clinical trials website</description>
  </link>
  <results_reference>
    <citation>Willis F, Theti D, Dean S, Bacon P, Baker N, Pettengell R. Pegfilgrastim successfully mobilizes megakaryocyte progenitors into the peripheral blood in subjects with solid tumours. Bone Marrow Transplant. 2008 Aug;42(3):167-73. doi: 10.1038/bmt.2008.147. Epub 2008 May 26.</citation>
    <PMID>18500375</PMID>
  </results_reference>
  <results_reference>
    <citation>Willis F, Woll P, Theti D, Jamali H, Bacon P, Baker N, Pettengell R. Pegfilgrastim for peripheral CD34+ mobilization in patients with solid tumours. Bone Marrow Transplant. 2009 Jun;43(12):927-34. doi: 10.1038/bmt.2008.411. Epub 2009 Jan 26.</citation>
    <PMID>19169289</PMID>
  </results_reference>
  <verification_date>May 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 30, 2005</study_first_submitted>
  <study_first_submitted_qc>June 30, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 7, 2005</study_first_posted>
  <last_update_submitted>May 9, 2013</last_update_submitted>
  <last_update_submitted_qc>May 9, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 13, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>solid tumour</keyword>
  <keyword>unknown primary tumour</keyword>
  <keyword>carboplatin</keyword>
  <keyword>paclitaxel</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

